Lingyi Sun

Lingyi Sun is a Senior Advisor at Eli Lilly and Company, leveraging a robust background in chemistry to spearhead research on antibody drug conjugates and related pharmaceuticals. Previously, they served as a Postdoctoral Associate at the University of Pittsburgh School of Medicine, where they developed novel pharmaceuticals and supervised visiting scholars. Lingyi earned a Ph.D. in Medicinal Chemistry from the National University of Singapore, where they also advanced the development of therapeutic enzyme inhibitors. Their extensive experience includes roles at Bristol Myers Squibb and Oregon Health and Science University, contributing significantly to cancer treatment innovations and publishing multiple research papers.